Industrial Viral Vector Manufacturing Using Advanced Process Analytical Technologies

Cell and gene therapies offer unprecedented promise for the cure, treatment or long term management of disease. However, the challenge facing the industry is the need for viral vectors which can be consistently manufactured to commercial scale with rigorous tolerances for purity, potency and safety. This collaboration to support advanced therapies is led by Oxford BioMedica (OXB) and includes 2 UK SME's; using OXB's existing leadership position in the development and manufacture of lentiviral vectors to meet in-house and partner organisation needs. Our aim is the development and application of novel advanced technologies to further evolve the current manufacturing platform, leading to an increase in the ability to deliver high quality vector for clinical and commercial applications. The project has the real potential to deliver tangible benefits to patients in shortening time-to-clinic and time-to-market as well as to improve the cost and access of bringing these novel therapies to patients. Each partner holds proprietary technology and know-how which will be leveraged to develop this innovative approach to viral vector manufacturing. The partners will look to access new market opportunities in cell and gene therapy resulting in economic growth and increased employment of highly skilled staff. The exploitable outcomes of this innovative project are closely aligned with the current government national priorities to make the UK a global hub for manufacturing advanced therapies.